Efaproxiral (Allos Therapeutics)

IDrugs. 2003 Aug;6(8):795-801.

Abstract

Allos Therapeutics Inc is developing the hemoglobin allosteric modifier efaproxiral as a potential radiosensitizer and chemotherapy enhancer in cancer therapy.

Publication types

  • Review

MeSH terms

  • Aniline Compounds / adverse effects
  • Aniline Compounds / chemical synthesis
  • Aniline Compounds / pharmacology*
  • Aniline Compounds / therapeutic use
  • Animals
  • Clinical Trials, Phase I as Topic
  • Clinical Trials, Phase II as Topic
  • Clinical Trials, Phase III as Topic
  • Contraindications
  • Humans
  • Neoplasms / radiotherapy*
  • Propionates / adverse effects
  • Propionates / chemical synthesis
  • Propionates / pharmacology*
  • Propionates / therapeutic use
  • Radiation-Sensitizing Agents / adverse effects
  • Radiation-Sensitizing Agents / chemical synthesis
  • Radiation-Sensitizing Agents / pharmacology*
  • Radiation-Sensitizing Agents / therapeutic use
  • Structure-Activity Relationship

Substances

  • Aniline Compounds
  • Propionates
  • Radiation-Sensitizing Agents
  • efaproxiral